Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status-Reference-Cited by-同舟云学术

Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status

Published:2019-11 Issue: Volume:80 Page:101909
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Tomao Federica,Bardhi Erlisa^ORCID,Di Pinto Anna,Sassu Carolina Maria,Biagioli Elena,Petrella Maria Cristina,Palaia Innocenza,Muzii Ludovico,Colombo Nicoletta,Panici Pierluigi Benedetti

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference29 articles.

1. Integrated genomic analyses of ovarian carcinoma;Cancer Genome Atlas Research Network;Nature,2011

2. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer;Morgan;Cancer Chemother Pharmacol,2018

3. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas;Pennington;Clin Cancer Res,2014

4. Niraparib in ovarian cancer: results to date and clinical potential;Caruso;TherAdv Med Oncol.,2017

5. Homologous recombination deficiency and ovarian cancer;Ledermann;Eur J Cancer,2016

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature;Frontiers in Oncology;2024-08-02

2. ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner;Cell Proliferation;2024-05-21

3. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2;International Journal of Clinical Oncology;2024-03-17

4. How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature;Frontiers in Oncology;2024-03-08

5. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis;Expert Review of Anticancer Therapy;2024-01-04